We discuss speculation surrounding the new Community Pharmacy Agreement and why successive governments support the framework approaching its 35th year. Community pharmacies are a good partner for the government, and so is the industry, but for a very different reason. We also urge the industry to be true to its stated commitment to patients and publicly explain its concerns about the HTA review options paper.
Latest Video
New Stories
-
The industry is probably right to resist, it just needs to prepare for the response
December 16, 2025 - - Latest News -
Cynata completes patient enrolment in Phase 2 trial for aGvHD therapy
December 15, 2025 - - Australian Biotech -
Prescient secures European approval to launch PTX-100 trial for rare lymphoma
December 15, 2025 - - Australian Biotech -
Orthocell lodges European and UK regulatory application for Remplir
December 15, 2025 - - Australian Biotech -
Neuren wins second FDA approval for trofinetide with launch of formulation
December 15, 2025 - - Australian Biotech -
Dimerix completes adult recruitment in Phase 3 trial for FSGS treatment DMX-200
December 15, 2025 - - Australian Biotech -
Radiopharm Theranostics reports high success rate in Phase 2b imaging trial
December 15, 2025 - - Australian Biotech
